More than 60 years of engagement for a better near patient diagnostics

Investor relations

Boule Diagnostics develops and manufactures diagnostic instruments and consumables for healthcare providers worldwide. The investor pages at contain published financial information, relevant links and provide information to facilitate investment decisions.
We are happy to assist you in understanding our business and financial results. Please do not hesitate to contact us if you would like more information.

Press Releases

Financial targets

  • Long term growth in sales above 10 percent per year
  • An operating margin (EBIT-margin) above 15 percent
  • Net debt (interest bearing debts minus cash and cash equivalents) no greater than three times operating profit (EBIT) on an annualized basis.
  • The annual dividend should correspond to 25-50 percent of profit for the period, after due consideration of company liquidity.

Boule share

Boule Diagnostics’ share were listed on NASDAQ Stockholm, on June 23, 2011. The number of shareholders is as of March 31, 2024 2,537.

Financial reports

Here you will find Boules financial reports. Last published report is the Interim report Q1

  • Interim report
  • Annual report
  • Year-end report

Financial Calendar

In Boule´s financial calendar you can see dates for our reports.

  • Interim report Q2, 22 July
  • Interim report Q3, 25 October
  • Interim report Q4, 11 February

Investor relations contact

For all investor relations related questions

Corporate governance

Boule is a Swedish public company. Boule applies the Swedish Companies Act and its rules and regulations. The company also follows the regulations that apply to listed companies with the NASDAQ OMX Nordic Exchange as well as the Swedish Code of Corporate Governance (the ”Code”). The Code applies to all Swedish listed companies whose shares are listed with a regulated market in Sweden. The code is based on principles of compliance. The company does not expect to deviate from the Code.

Boule as an investment

Boule operates via subsidiaries in Sweden, the USA, Mexico and Russia. The company products are sold globally primarily through more than 200 distributors and partners in more than 100 countries, supported by Boule’s own local sales and support personnel. The Boule shares are listed on Nasdaq Stockholm since 2011

Boule Diagnostics resolves on a fully secured preferential rights issue of approximately SEK 150 million

548.1 MSEK

Net sales


Operating profit

41,6 %

Gross margin

13.3 MSEK

Operating cash flow